#1 Clinical Trials Search in Europe

Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

↓

Matched clinical trials

  • Study on Dacarbazine, Pembrolizumab, Nivolumab, and Ipilimumab for Patients with Unresectable or Metastatic Melanoma Resistant to Immunotherapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Germany

  • Study of RO7247669 at Different Doses for People with Previously Untreated Advanced Melanoma that Cannot be Removed by Surgery or Has Spread

    Not recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    Czechia Greece Poland Slovakia Spain

  • Study on Binimetinib, Encorafenib, and Pembrolizumab for Patients with BRAF V600 Mutation-Positive Melanoma and Brain Metastasis

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France

  • Study of INCB099280 and Ipilimumab for Patients with Advanced Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Norway Slovakia Sweden

  • Study Comparing Relatlimab and Nivolumab Combination vs. Nivolumab Alone for Patients with Advanced Melanoma

    Not recruiting

    4 1 1 1
    Investigated Drugs:
    Austria Belgium Denmark Finland France Germany +7

  • Study of IO102-IO103 and Pembrolizumab for Patients with Advanced Melanoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium Czechia Denmark France Germany Hungary +4

  • Study on the Safety and Effects of ATL001 and Nivolumab for Adults with Metastatic or Recurrent Melanoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Spain

  • Study on the Effectiveness and Safety of RO7198457 and Pembrolizumab for Patients with Untreated Advanced Melanoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Germany Spain

  • Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with Advanced Melanoma with BRAF V600E/K Mutation

    Not recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium Bulgaria Czechia Finland Germany Greece +5

  • Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with BRAF V600E/K Mutation-Positive Melanoma After Anti-PD-1 Therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Germany Italy Poland Slovakia Spain